Smad4 deficiency can lead to rapid progression of pancreatic tumors in the context of activated KrasG12D; however, Smad4 deficiency alone is incapable of initiating pancreatic tumorigenesis and dispensable for normal pancreas development [13–15]. Here, SMAD4 is linked to pancreatic neoplasm.